



## Declaration of Reasons for Premature End

**Clinical trial EudraCT:** 2019-003575-19

**Sponsor's Protocol Code Number:** 4SC-202-4-2019

**Title:** A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel Cell Carcinoma - the MERKLIN1 Study

4SC AG  
Fraunhoferstr. 22  
82152 Planegg-Martinsried  
Germany

Phone: +49 89 700763-0  
Fax: +49 89 700763-29

public@4sc.com  
www.4sc.com

30 November 2021

As a result of a scheduled review of the sponsor's program for the clinical development of domatinostat the sponsor has decided to focus resources exclusively on either checkpoint inhibitor naïve patients in curative, resectable stages of disease, and on patients with metastatic relapsed/refractory disease that has progressed on previous therapy.

No safety concern or change of the risk-benefit assessment of the investigational medicinal product has led to this decision.

With regards to the Merkel cell carcinoma development program this means that further activities on the MERKLIN 1 trial in metastatic first line setting has been stopped and patient enrolment will not be started.

Due to the termination of the clinical trial before the first patients has been included, there will be no results.

A handwritten signature in black ink, appearing to read 'S. Danhauser-Riedl'.

Dr. med. Susanne Danhauser-Riedl  
Chief Medical Officer

[susanne.danhauser-riedl@4sc.com](mailto:susanne.danhauser-riedl@4sc.com)

+49 89 700763-0

Management  
Dr Jason Loveridge

Chairman of the  
Supervisory Board  
Dr Clemens Doppler

Commercial Register  
HRB 132 917  
District Court of Munich

VAT ID No.: DE 211 603 775  
VAT No.: 143/101/80646

IBAN (Deutsche Bank):  
DE54700700100199050600  
SWIFT: DEUTDEMM